Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies

Open to people ages 18-130

• Age ≥ 18 at the time of screening
• Histological or cytological confirmation of advanced malignancy considered to be suitable for study treatment and meeting module specific eligibility criteria..
• Eastern Cooperative Oncology Group Performance status (ECOG PS: 0-2)
• Life expectancy ≥ 12 weeks
• Progressive cancer at the time of study entry
• Patients must have evaluable disease as per RECIST v1.1
• Adequate organ and marrow function as defined by the protocol.
• For expansion cohorts: Provision of formalin-fixed and paraffin embedded (FFPE) tumour specimen is mandatory except if stated that it is optional in a specific Module.

For Part A:

• Patients may have received up to one prior line of therapy with a PARPi-based regimen (either as a treatment or as maintenance)

For Part B:

• Patients must not have received prior therapy with a PARPi-based regimen (either as a treatment or as maintenance).

• Treatment with any of the following:
• Nitrosourea or mitomycin C within 6 weeks of the first dose of study treatment
• Any investigational agents or study drugs from a previous clinical study within 5 half-lives or 3 weeks (whichever is longer) of the first dose of study treatment
• Any other chemotherapy, immunotherapy or anticancer agents within 3 weeks of the first dose of study treatment
• Any live virus or bacterial vaccine within 28 days of the first dose of study treatment
• Concomitant use of medications or herbal supplements known to be cytochrome P450 3A4 (CYP3A4) strong and moderate inhibitors or inducers.
• Concomitant use of drugs that are known to prolong or shorten QT and have a known risk of Torsades de Pointes.
• Receiving continuous corticosteroids at a dose of >10 mg prednisone/day or equivalent for any reason.
• Major surgery within 4 weeks of the first dose of study treatment.
• Radiotherapy with a wide field of radiation within 4 weeks or radiotherapy with a limited field of radiation for palliation within 2 weeks of the first dose of study treatment.
• Any history of persisting (> 2 weeks) severe pancytopenia due to any cause
• Spinal cord compression or brain metastases unless asymptomatic, treated and stable and not requiring continuous corticosteroids at a dose of >10mg prednisone/day or equivalent for at least 4 weeks prior to start of study treatment
• Cardiac conditions as defined by the clinical study protocol
• Other cardiovascular diseases as defined by any of the following:
• Symptomatic heart failure,
• uncontrolled hypertension,
• hypertensive heart disease with significant left ventricular hypertrophy
• acute coronary syndrome (ACS)/acute myocardial infarction (AMI), unstable angina pectoris, coronary intervention procedure with percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) within 6 months.
• cardiomyopathy of any etiology
• presence of clinically significant valvular heart disease
• history of atrial or ventricular arrhythmia requiring treatment.
• subjects with atrial fibrillation and optimally controlled ventricular rate are permitted
• transient ischaemic attack, or stroke within 6 months prior to screening
• . patients with symptomatic hypotension at screening
• Patients with myelodysplastic syndrome/acute myeloid leukaemia or with features suggestive of myelodysplastic syndrome (MDS)/acute myeloid leukaemia (AML).
• Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption of AZD5305
• Known allergy or hypersensitivity to investigational product(s) or any of the excipients of the investigational product(s)